Firefly Neuroscience (NASDAQ: AIFF) announced research advancement using its FDA-cleared Evoke System to potentially distinguish between three main subtypes of attention-deficit/hyperactivity disorder through EEG brain scans.

The company stated its AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has among hyperactive and impulsive, inattentive, and combined types. Current ADHD diagnosis relies on symptom-based criteria without objective biological tools for subtype differentiation, according to the company.

ADHD affects over 22 million Americans and represents a U.S. treatment market estimated at over $10 billion. Healthcare professionals currently use the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) to distinguish between ADHD types based on symptom patterns lasting more than six months.

"Some types of ADHD respond well to stimulants, while others don't and neurofeedback therapy may be recommended instead," said Gil Issachar, Chief Technology Officer of Firefly. "Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations."

The methodology is supported by prior research published in Frontiers in Psychiatry demonstrating diagnostic utility of EEG-based brain activity analysis in ADHD patients, the company stated.

Firefly maintains a database of over 191,000 EEG/ERP brain scans and is developing what it describes as the world's first EEG/ERP-based foundation model of the human brain. The company's technology has FDA 510(k) clearance for brain analytics applications.

Chief Executive Officer Greg Lipschitz said the discovery demonstrates how the company is "harnessing the power of AI and EEG/ERP to potentially transform neuroscience and clinical development."